WebFeb 24, 2024 · OrbiMed and Oceanpipe Lead USD130m Series B for China’s Yisheng Biopharma 24 February 2024 Source (s): DealStreetAsia OrbiMed and Oceanpipe Capital led a USD130m Series B for China-based biopharmaceutical company Yisheng Biopharma. Read more for GPCA’s newsletters NewsWatch WebMarketplace is a convenient destination on Facebook to discover, buy and sell items with people in your community.
Yisheng moves COVID-19 vaccine to clinic after $130M series
WebDec 7, 2024 · BOSTON, Dec. 7, 2024 /PRNewswire/ -- Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the completion of an oversubscribed $218 million Series A financing led by OrbiMed Advisors and co-led by SR One Capital Management with participation from … WebSep 28, 2024 · BioShin Limited, a privately-held biopharmaceutical company with offices in Shanghai, is advancing the Biohaven clinical portfolio in the Asia-Pacific region. BioShin holds rights to the Biohaven... chudleigh dog grooming
YishengBio Raises $130 Million in Series B Funding to
WebOrbiMed's team includes over 100 experienced professionals with expertise in the life sciences industry, medicine, finance, and law. This complementary mix of deep operating skills, investment experience, and scientific acumen provides the firm with a solid foundation from which to seek successful investments. WebMar 2, 2024 · China’s Yisheng Biopharma Ltd has closed its $130-million Series B round co-led by returning investor OrbiMed and deep tech-focused investor Oceanpine Capital. Yisheng had raised an undisclosed sum in its Series A round funding from Eight Roads back in 2012. Chinese investment bank CEC Capital served as the financial advisor for the deal, … WebMar 3, 2024 · Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline Financing led by Casdin Capital and joined by Fidelity Management ... chudleigh dog food